1. Introduction {#s0005}
===============

Connecting individuals with substance use disorders (SUD) to evidence-based treatment is a key challenge in the U.S. ([@bb0005]) In 2017, only 20% of individuals who needed substance use treatment for alcohol or illicit drug use, received it ([@bb0060]). Barriers to treatment include limits on insurance coverage, stigma, and provider shortages---in particular waivered providers who prescribe medications for opioid use disorder (OUD) (e.g., buprenorphine) ([@bb0050]). Access challenges are particularly problematic in rural and other underserved communities ([@bb0030]).

Telemedicine, in the form of live videoconferencing with a clinician, is a potential solution ([@bb0010]; [@bb0040]; [@bb0045]; [@bb0055]; [@bb0070]). Treatment facilities in underserved areas can leverage telemedicine for SUD services to enable access to care that otherwise would not be available. Telemedicine services in this setting can include individual and group treatments, such as medication management, counseling, psychotherapy, and case management. Regulatory barriers have inhibited telemedicine for SUD, most notably from the Ryan Haight Act, which restricts prescribing controlled substances, such as buprenorphine, through telemedicine. Recent policy changes such as the 2018 SUPPORT Act have begun to eliminate many of these regulatory and reimbursement barriers to delivering telemedicine for SUDs. Though use rates remain low, recent work has highlighted the rapid growth of telemedicine for SUD ([@bb0035]).

Despite this growth, little is known about adoption of telemedicine for SUD. Many factors may influence adoption, including the local provider workforce and local policy environment (e.g., whether visits are reimbursed). To date, there is little evidence on telemedicine adoption by SUD treatment facilities and how it varies across geography and different patient populations. To address this gap in the literature, we studied trends in licensed treatment facilities\' adoption of telemedicine and how adoption varies across local factors, including county-level drug overdose rates, urbanicity measures, and state policy laws.

2. Methods {#s0010}
==========

We analyzed data from the National Directory of Drug and Alcohol Abuse Treatment Facilities, which the Substance Abuse and Mental Health Services Administration (SAMHSA) publishes annually. The directory includes all licensed SUD treatment facilities that participated in the previous year\'s National Survey of Substance Abuse Treatment Services (N-SSATS) and agreed to be listed. In 2018, 14,809 facilities participated in the N-SSATS for a response rate of 92% ([@bb0065]). The directory includes location of the facility, service setting, facility ownership, patient population, and the types of treatment available. We limited our sample to licensed treatment facilities that provided SUD treatment and reported on their adoption of telemedicine each year (83% of participating facilities).

Our main outcome was telemedicine use by a SUD facility. This was defined as facilities that "sometimes" or "always or often" used "computerized substance abuse treatment/telemedicine," which was asked as part of a checklist of items under the heading "Which of these clinical/therapeutic approaches are offered at this facility?" SAMHSA interprets this question as providing information on whether facilities provide telemedicine, and includes a filter on telemedicine use (yes/no) based on this question in its publicly available Behavioral Health Treatment Services Locator database ([@bb0015]). We also captured independent variables from other datasets, including estimated county-level drug poisoning death rates from the National Vital Statistics System ([@bb0025]); state-level telemedicine policy regarding coverage and reimbursement in 2016 using published American Telemedicine Association (ATA) grades (A,B,C) ([@bb0075]); and the presence of a telemedicine parity law (yes/no) that required private payers to reimburse for telemedicine ([@bb0020]).

We calculated the unadjusted proportion of facilities offering telemedicine from 2016 to 2019. Using chi-squared tests, we compared adoption rates by year. We estimated a multivariable logistic regression model to determine which facility characteristics were associated with offering telemedicine in 2019, the most recent year for which data were available. The unit of analysis was the facility, and the outcome was whether the facility offered telemedicine services in 2019. Variables in the model were U.S. region, urbanicity, treatment setting (inpatient only, residential only, outpatient only, multiple), SUD pharmacotherapy services offered, Medicaid acceptance, drug-related mortality rate in the county, facility ownership, patient populations served, state ATA grade, and state telemedicine parity law. We used robust standard errors, clustered at the state level. Harvard\'s Institutional Review Board declared this study to be exempt from review.

3. Results {#s0015}
==========

From 2016 to 2019, an average of 12,334 treatment facilities were included in our sample. Over the four-year period, the unadjusted proportion of facilities that reported offering telemedicine grew from 13.5% in 2016 to 17.4% in 2019 (p \< 0.001). In 2019, there was wide state-to-state variation in facility adoption of telemedicine; \<7% of facilities in Connecticut, Hawaii, Rhode Island, and Vermont offered tele-SUD services compared to \>40% in Alaska, Missouri, and Wyoming ([Fig. 1](#f0005){ref-type="fig"} ).Fig. 1Proportion of substance abuse treatment facilities offering telemedicine for SUDs by state.Fig. 1

Facilities offering telemedicine differed from those that did not in several ways. In adjusted models, rural location; offering multiple treatment settings; offering pharmacotherapy; and serving both adult and pediatric patients were associated with greater telemedicine adoption (p \< 0.05 for all comparisons) ([Table 1](#t0005){ref-type="table"} ). Notable differences included rural location, with 22.4% of facilities in rural areas offering telemedicine vs. 15.8% in metropolitan areas (p \< 0.001); and pharmacotherapy offered, with 21.0% of facilities that offered naltrexone, methadone, buprenorphine, acamprosate, and/or disulfiram offering telemedicine vs. 14.2% that did not offer any of these pharmacotherapy services (p \< 0.001). There were no statistically significant differences in facility telemedicine adoption across state-level telemedicine policy variables, county drug-related mortality rate, Medicaid acceptance, or facility ownership.Table 1Characteristics of substance abuse treatment facilities by telemedicine adoption.Table 1Tele-SUD offered (n = 2247)Tele-SUD not offered (n = 10,660)Adjusted odds ratio95% confidence intervaln%n%U.S. regionMidwest59918.8258481.2RefNortheast29511.3230788.70.50[⁎⁎⁎](#tf0035){ref-type="table-fn"}\[0.43,0.59\]South70820.4276579.61.07\[0.94,1.22\]West64517.7300482.30.93\[0.80,1.07\]  Metropolitan location[a](#tf0005){ref-type="table-fn"}Metropolitan153115.8817384.2RefNot metropolitan71622.4248777.61.51[⁎⁎⁎](#tf0035){ref-type="table-fn"}\[1.36,1.68\]  Type of treatment centerOutpatient only160116.9788383.1RefHospital inpatient only178.318791.70.42[⁎⁎⁎](#tf0035){ref-type="table-fn"}\[0.25,0.70\]Residential only28815.6155984.41.12\[0.97,1.30\]Multiple settings34124.9103175.11.49[⁎⁎⁎](#tf0035){ref-type="table-fn"}\[1.30,1.72\]  Pharmacotherapy servicesDoes not offer SUD medications[b](#tf0010){ref-type="table-fn"}98114.2590585.8RefOffers one or more SUD medications126621.0475579.01.85[⁎⁎⁎](#tf0035){ref-type="table-fn"}\[1.67,2.04\]  Forms of paymentDoes not accept Medicaid69716.5354083.5RefAccept Medicaid155017.9712082.11.09\[0.97,1.22\]  Drug-related mortality[c](#tf0015){ref-type="table-fn"}Location (county) in bottom tertile for drug related mortality rate72416.5365783.5RefLocation (county) in top tertile for drug related mortality rate92817.3442682.71.13[⁎](#tf0025){ref-type="table-fn"}\[1.01,1.27\]  Patient populationServes children (no age limit or 10+)107718.3482181.7RefServes adults only (17+)117016.7583983.30.82[⁎⁎⁎](#tf0035){ref-type="table-fn"}\[0.73,0.91\]  Facility ownershipGovernment23419.695880.4RefPrivate for-profit organization89317.9410982.11.05\[0.89,1.25\]Private non-profit organization112016.7559383.30.97\[0.83,1.14\]  American Telemedicine Association Grade for State (2016)[d](#tf0020){ref-type="table-fn"}A25318.1114381.9RefB163417.6764082.41.08\[0.93,1.27\]C36016.1187783.90.9\[0.73,1.10\]  Telemedicine Parity Law (2016)No85117.0414283.0RefYes139617.6651882.41\[0.90,1.12\][^1][^2][^3][^4][^5][^6]

4. Discussion {#s0020}
=============

Although adoption of telemedicine is increasing, \<20% of licensed treatment centers offered telemedicine services by 2019. This adoption rate is lower than the adoption rate for telemedicine by other healthcare organizations; in 2016, 26% of all mental health facilities ([@bb0085]) and 58% of all hospitals reported using telemedicine for different health conditions ([@bb0080]). Several factors may explain SUD facilities\' lower adoption of telemedicine, including patient acceptance, patient and provider awareness of telemedicine, regulatory restrictions on prescribing controlled medications via telemedicine (which the SUPPORT Act addresses, but it has not yet been fully implemented), and constrained resources to purchase the telemedicine infrastructure ([@bb0085]).

There was notable state-to-state variation in uptake and treatment facilities located in rural areas, and those that offered pharmacotherapy services had higher rates of adoption. However, despite the opportunity that telemedicine offers for SUD pharmacotherapy, we note the very low rates of pharmacotherapy adoption overall, and among SUD providers who use telemedicine. The fact that facilities treating both adults and children were more likely to adopt telemedicine could reflect the use of telemedicine to bring in pediatric expertise (e.g., pediatric psychiatrists) that may be lacking in the community.

Data for this study were collected prior to the COVID-19 pandemic. The pandemic is likely to have a major impact on telemedicine adoption, as facilities implement social distancing and various regulatory and reimbursement barriers to telemedicine are relaxed. Future research is needed to examine changes in telemedicine adoption beyond 2020, and this study provides important information about the state of telemedicine in substance use treatment facilities pre-COVID-19.

Our study had several limitations. First, our analysis was limited to licensed facilities. Second, we do not know how facilities are using telemedicine, and given how the survey question was worded, respondents may also interpret digital services (e.g., online psychoeducation resources) as telemedicine.

4.1. Public health implications {#s0025}
-------------------------------

Telemedicine use is growing steadily among licensed treatment facilities; however, uptake is uneven and relatively low compared to telemedicine adoption among other healthcare organizations. As such, telemedicine may be an underutilized tool to expand access to care for patients with SUDs. Further research is needed on what drives facilities to invest in telemedicine for SUDs and to examine its effectiveness.
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[^1]: Calculated using National Center for Health Statistics Urban-Rural Classification Scheme for Counties.

[^2]: Defined as not offering any of the following medications: Naltrexone, Methadone, Buprenorphine, Acamprosate or Disulfiram.

[^3]: Calculated using National Vital Statistics System multiple cause-of-death mortality files.

[^4]: ATA grade captures the extent to which state policies governing the Medicaid program and private payers are telemedicine friendly. The ATA grade accounts for various restrictions on the practice and reimbursement of telemedicine services.

[^5]: p \< 0.05.

[^6]: p \< 0.001.
